NASDAQ:NLSP NLS Pharmaceutics (NLSP) Stock Price, News & Analysis $0.14 +0.00 (+2.19%) (As of 11:38 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get NLS Pharmaceutics alerts: Email Address About NLS Pharmaceutics Stock (NASDAQ:NLSP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NLS Pharmaceutics alerts:Sign Up Key Stats Today's Range$0.14▼$0.1550-Day Range$0.12▼$0.2452-Week Range$0.11▼$1.02Volume55,058 shsAverage Volume4.46 million shsMarket Capitalization$1.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.Read More… Shocking prediction from firm that predicted President Kamala (Ad)Prepare for President Kamala I won't be voting for her. Even so, I'm worried VP Kamala Harris could pull off a victory and become our next president. And it would be much worse than anything you might expect—especially when it comes to your money. Because likely WON'T get a second chance at recovering the money you stand to lose if she takes power.Find out how to prepare. NLS Pharmaceutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 13th PercentileNLS Pharmaceutics scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for NLS Pharmaceutics.Read more about NLS Pharmaceutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioNLS Pharmaceutics has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.99% of the float of NLS Pharmaceutics has been sold short.Short Interest Ratio / Days to CoverNLS Pharmaceutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NLS Pharmaceutics has recently decreased by 25.62%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNLS Pharmaceutics does not currently pay a dividend.Dividend GrowthNLS Pharmaceutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.99% of the float of NLS Pharmaceutics has been sold short.Short Interest Ratio / Days to CoverNLS Pharmaceutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NLS Pharmaceutics has recently decreased by 25.62%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A MarketBeat FollowsOnly 1 people have added NLS Pharmaceutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NLS Pharmaceutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.40% of the stock of NLS Pharmaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about NLS Pharmaceutics' insider trading history. Receive NLSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NLSP Stock News HeadlinesWhy Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?July 29, 2024 | investorplace.comNLS Pharmaceutics to Absorb Kadimastem as Subsidiary After Agreeing to MergerJuly 29, 2024 | marketwatch.comShocking prediction from firm that predicted President KamalaPrepare for President Kamala I won't be voting for her. Even so, I'm worried VP Kamala Harris could pull off a victory and become our next president. And it would be much worse than anything you might expect—especially when it comes to your money. Because likely WON'T get a second chance at recovering the money you stand to lose if she takes power.September 20, 2024 | Stansberry Research (Ad)Kadimastem To Become Subsidiary Of NLS; Kadimastem Shareholders To Hold 85% Of Merged Company SharesJuly 29, 2024 | markets.businessinsider.comNLSP NLS Pharmaceutics AGJuly 26, 2024 | seekingalpha.comWhy Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?June 20, 2024 | investorplace.comWhy Is NLS Pharmaceutics (NLSP) Stock Up 163% Today?June 18, 2024 | investorplace.comNLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol's Neuroprotective Effects in Narcoleptic-like Rat ModelMay 28, 2024 | stockhouse.comSee More Headlines NLSP Stock Analysis - Frequently Asked Questions How have NLSP shares performed this year? NLS Pharmaceutics' stock was trading at $0.5899 at the beginning of 2024. Since then, NLSP shares have decreased by 76.7% and is now trading at $0.1372. View the best growth stocks for 2024 here. When did NLS Pharmaceutics IPO? NLS Pharmaceutics (NLSP) raised $20 million in an initial public offering on Friday, January 29th 2021. The company issued 3,600,000 shares at $5.00-$6.00 per share. Maxim Group LLC served as the underwriter for the IPO and Brookline Capital (A division of Arcadia Securities) was co-manager. Who are NLS Pharmaceutics' major shareholders? Top institutional investors of NLS Pharmaceutics include Armistice Capital LLC (19.62%). How do I buy shares of NLS Pharmaceutics? Shares of NLSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today9/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NLSP CUSIPN/A CIK1783036 Webwww.nlspharma.com Phone41-44-512-2150Fax41-41-618-8009Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.23 Quick Ratio0.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book0.49Miscellaneous Outstanding Shares11,780,000Free FloatN/AMarket Cap$1.61 million OptionableNot Optionable Beta-0.56 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:NLSP) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredNew President Kamala warningFinancial nightmare coming after election In 2018, one independent research predicted Kamala Harris was on ...Stansberry Research | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredAct by Friday, August 16th, to collect this 22% dividendLet's do a little math here... To double your money at a 3% rate of return, you would need around 23 years....Investors Alley | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.